In the interim, however, with PD-L1 expression still the only validated biomarker for predicting response of NSCLC to anti-PD-1/PD-L1 IMs, an optimal approach to improved tumour sampling may be guided by the intended therapeutic target. This evidence concerns the gene CD274 and non-small cell lung carcinoma.